Neurocrine Biosciences, Inc. $NBIX Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,522 shares of the company’s stock after selling 4,884 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $5,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Royal Bank of Canada grew its stake in Neurocrine Biosciences by 36.7% during the 1st quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock worth $9,158,000 after purchasing an additional 22,224 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Neurocrine Biosciences by 60.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after buying an additional 5,577 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 56.3% in the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after buying an additional 2,747 shares during the period. Empowered Funds LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth about $1,333,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $177.11 on Monday. The firm’s fifty day moving average price is $160.84 and its 200 day moving average price is $142.87. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $181.18. The company has a market capitalization of $17.81 billion, a price-to-earnings ratio of 27.29, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of recent analyst reports. Sanford C. Bernstein began coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price objective on the stock. Zacks Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 price target on the stock. Royal Bank Of Canada lifted their price target on Neurocrine Biosciences from $183.00 to $195.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Truist Financial upped their price objective on Neurocrine Biosciences from $140.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.10.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX continues to draw bullish attention for its growth profile, with one article highlighting three reasons growth investors shouldn’t overlook Neurocrine and another pointing to strong sales and pipeline progress as reasons the stock has been trending higher. Article Title Article Title
• Positive Sentiment: Recent coverage on Phase 2 CAH study activity in young children suggests Neurocrine’s pipeline is advancing, and one note said the stock could be undervalued after the new study. Article Title Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with recent upgrades and higher price targets reinforcing confidence in NBIX’s earnings outlook and growth prospects. Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30, which is an upcoming catalyst but not a fundamental change by itself. Article Title
• Neutral Sentiment: A report that NBIX looks fair on earnings but expensive relative to other biotech names is mainly a valuation check and may limit enthusiasm, but it is not a direct negative catalyst. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in multiple transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which makes the signal less concerning, but insider selling can still weigh on sentiment. Article Title

Insider Activity at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 245,088 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the completion of the sale, the director directly owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. The trade was a 32.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $165.32, for a total value of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at approximately $2,621,975.20. This trade represents a 61.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 379,805 shares of company stock valued at $59,634,666. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.